

Extraskelatal myxoid chondrosarcoma of the external auditory meatus

K Aroni, A Nonni, C Bakogiannis, A Lazaris

Citation

K Aroni, A Nonni, C Bakogiannis, A Lazaris. *Extraskelatal myxoid chondrosarcoma of the external auditory meatus*. The Internet Journal of Pathology. 2008 Volume 8 Number 2.

Abstract

Extraskelatal myxoid chondrosarcoma (EMC) is an uncommon but distinct entity with clearly different clinicopathological, immunohistochemical, cytogenetical and histogenetical features from conventional skeletal chondrosarcoma. Because of its better prognosis in comparison to conventional skeletal chondrosarcoma, the right diagnosis is essential. A case of EMC occurring in the external auditory meatus, coexistent with in situ squamous carcinoma of the covering epithelium is being presented. This is the first report of this tumor coexistence.

INTRODUCTION

Extraskelatal myxoid chondrosarcoma is an unusual but distinct entity characterized by special clinicopathological, immunohistochemical, and cytogenetical features, first described in 1953 by Stout and Verner [1]. It is a low-grade soft tissue sarcoma, locally aggressive and potentially metastasizing [2]. EMC is a tumor mostly affecting the deep soft tissues adjacent to the bones of the extremities, especially the lower one, and is rarely seen in other sites, such as pelvis, shoulder, chest wall, sinonasal tract [3], nasopharynx [4], jugular foramen, clavicle [5] and orbit. We are going to present a case of an EMC occurring in the external auditory meatus, which is the second one referred in the literature, located in this site [6] and, to the best of our knowledge, the first one coexistent with in situ squamous carcinoma of the covering epithelium.

CASE REPORT

A 74-year-old man admitted to the Hospital with a mass in the left external auditory meatus, causing poor hearing. CT scan showed a soft tissue mass filling left external meatus. The patient underwent resection of this mass, which was measuring 4.5 cm in maximum diameter.

PATHOLOGY

Gross examination revealed a whitish lobulated mass with some hemorrhagic areas. The cut surface displayed a partly myxoid appearance.

Sections showed dysplasia in the covering squamous

epithelium of the external auditory meatus, focally evolving to in situ squamous carcinoma. In the dermis, there was invasion of round to oval-shaped cells arranged in nests and strands within a myxoid, Alcian-blue-positive, stroma. The nuclei were hyperchromatic and the cytoplasm eosinophilic. Focally, the cells displayed epithelioid features with vesicular nuclei containing nucleoli. The mitotic activity was low.

Immunohistochemically, the tumor cells were positive for vimentin and neuron-specific-enolase, but negative for epithelial membrane antigen, cytokeratin, S-100 protein, synaptophysin, and chromogranin. Our findings were consistent with the immunophenotype of EMC, as this has been documented in previous studies [7]. Differential diagnosis includes conventional skeletal chondrosarcoma, chordoma, parachordoma, myxoid chordoid meningioma, mixed myoepithelial tumor and other soft tissue lesions with myxoid appearance.

DISCUSSION

The histogenesis of EMC remains unclear and controversial. In a recent study [8], it is suggested that the basic cellular phenotype of EMC is not chondrocytic or prechondrocytic, thus excluding its chondrosarcomatous nature. It is more likely consisted of primitive mesenchymal cells with focal, multidirectional differentiation. Previously, immunohistochemical and ultrastructural features of neural or neuroendocrine differentiation had been reported by some authors [9,10,11,12], arising a new insight into the histogenesis of

this tumor. Consequently, according to the revised version of the World Health Organization classification of tumors of soft tissue and bone, EMC is classified as a tumor of uncertain differentiation [13]. Cytogenetically, the translocation t(9;22) (q22-31)(q11-12) has been found in most EMC cases. Cranial cartilage is considered to be derived from pluripotential precursor cells of the neural crest; on the other hand, chondrocytes found elsewhere in the body are believed to be derived from mesoderm. Soft tissue tumors with cartilaginous differentiation may thus be related either to neural crest or mesoderm, depending on their anatomic location. The presumed origin of EMC is cartilage, and thus of mesodermal origin when it occurs in locations other than the head and neck; actually, S-100 immunoreactivity in such cartilaginous neoplasms has been attributed to their chondroid nature and hence mesodermal derivation [14]. The present case was located in the external auditory meatus and was S-100 negative; so, its mesodermal derivation is ambiguous. Peripherin is an intermediate filament apparently expressed exclusively in cells derived from the neural crest and neural tube. The peripherin immunostaining in a considerable portion of malignant cells implies that EMC of the head and neck may contain a subpopulation of cells with the ability to demonstrate neural differentiation in addition to chondroid differentiation, as suggested Cummings et al [14].

As far as the present case is concerned, it is noteworthy that in a non-sun exposed site two distinct morphological types of malignancy appeared in close proximity; the first one was in situ carcinoma and originated from squamous cells and the other was invasive and probably derived from primitive cells of uncertain origin.

EMC, which occurs in almost the same incidence in both sexes, with a peak in the fifth to seventh decades, seems to be a quite indolent but potentially metastasizing tumor, especially to the lung. Additionally, recurrences are frequent. However, its high rate of metastasis is not accompanied by decreased patient's survival. Studies have shown [7], that the 5-year survival rate is 91%, while the 10-year overall survival rate is 78%. The presence of some adverse prognostic factors such as tumor size ≥ 10 cm, high cellularity, anaplasia or rhabdoid features, mitotic activity more than two per 10 high-power fields, and Ki-67 $\geq 10\%$ indicates a possible more aggressive behavior, requiring a closer follow-up of the patient.

In summary, EMC is an uncommon but distinct entity,

clearly different from conventional skeletal chondrosarcoma. Its location at the external auditory meatus is extremely rare, as until now, there has been only one such report in the literature.

CORRESPONDENCE TO

Andreas C. Lazaris MD 1st Department of Pathology, School of Medicine National and Kapodistrian University of Athens 75 Mikras Asias Str, Goudi, GR-115 27 ATHENS Tel: +30210-7462167, Fax : +30210-7462157 e-mail: alazaris@med.uoa.gr / alazar65@otenet.gr

References

1. Stout AP, Verner EW (1953) Chondrosarcoma of the extraskelatal soft tissues. *Cancer* 6: 581.
2. Enzinger FM, Shiraki J (1972) Extraskelatal myxoid chondrosarcoma: an analysis of 34 cases. *Hum Pathol* 3: 421.
3. Ceylan J, Kizilkaya J and Yavanoglu A (2006) Extraskelatal myxoid chondrosarcoma of the nasal cavity. *Eur Arch of Otorhinolaryngol* 263(11): 1044.
4. Jerome-Marson V, Uro-Coste J, Lacoste-Collin L, Gomez-Bouchet A, Serrano E, Deliste MB (2003) Extraskelatal myxoid chondrosarcoma of the nasopharynx. *Ann Pathol* 23(3): 253.
5. Nakazora S, Kusuzaki K, Matsubara T, Shintani K, Matsumine A, Fukutome K, Uchida A (2006) Extraskelatal myxoid chondrosarcoma arising from the clavicle. *Oncol Rep* 16(1): 115.
6. Worley GA, Wareing MJ, Sergeant RJ (1999) Myxoid chondrosarcoma of the external auditory meatus. *J Laryngol Otol* 113(8): 742.
7. Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG, Nascimento AG (2000) Extraskelatal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical and ploidy analysis of 23 cases. *Mod Pathol* 13(8): 900.
8. Aigner T, Oliveira AM, Nascimento AG (2004) Extraskelatal myxoid chondrosarcomas do not show a chondrocytic phenotype. *Mod Pathol* 17(2): 214.
9. Okamoto S, Hisaoka M, Ishida T, Imamura T, Kanda H, Shimajiri S, Hashimoto H (2001) Extraskelatal myxoid chondrosarcoma: a clinicopathological, immunohistochemical, and molecular analysis of 18 cases. *Hum Pathol* 32: 1116.
10. Chhieng DC, Eriandson RA, Antonescu C, Ladanyi M, Rosai J (1998) Neuroendocrine differentiation in adult soft tissue sarcoma with features of extraskelatal myxoid chondrosarcoma: report of seven cases [abstract]. *Mod Pathol* 11:8A.
11. Goh YW, Spangnol DV, Flatten M, Caterina P, Fisher P, Oliveira AM, Nascimento AG (2001) Extraskelatal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation. *Histopathology* 39: 514.
12. Sjögren J, Meis-Kindbom JM, Omdal C, Bergh P, Ptaszynski K, Aman P, Kindblom LG, Stenman G (2003) Studies on the molecular pathogenesis of extraskelatal myxoid chondrosarcoma: cytogenetic, molecular genetic, and cDNA microarray analyses. *Am J Pathol* 162: 781.
13. Lucas DR, Heim S (2002) Extraskelatal myxoid chondrosarcoma. In: Fletcher CDM, Unni K, Martens F (eds) *World Health Organization Classification of Tumour*,

Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, pp 213-215.
14. Cummings TJ, Shea CR, Reed JA, Burchette JL, Prieto

VG (2000) Expression of the intermediate filament peripherin in extraskeletal myxoid chondrosarcoma. J Cutan Pathol 27:141.

Author Information

Kyriaki Aroni, MD

Associate Professor, 1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens

Aphrodite Nonni, MD

Clinical Lecturer, 1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens

Constantinos Bakogiannis, MD

1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens

Andreas C. Lazaris, MD

Assistant Professor, 1st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens